SOURCE: BioCentury Publications, Inc.

BioCentury Publications, Inc.

May 20, 2013 20:21 ET

The 14th Annual BioEquity Europe Conference Features 96 Innovator Companies With Differentiated Products, Upcoming Milestones and Partner-Ready Assets

Plenary Sessions Led by Industry Leaders in the Life Sciences Anchor 2 Days of Thought Provoking Program

REDWOOD CITY, CA--(Marketwired - May 20, 2013) - BioCentury, EBD Group and the Biotechnology Industry Organization (BIO) will convene the 14th Annual BioEquity Europe conference in Stockholm, Sweden on Wednesday, May 22, and Thursday, May 23, at the Sheraton Stockholm Hotel. Over 500 life science investment professionals and pharmaceutical business development and licensing executives already have pre-registered. Walk-up registration is available at the Sheraton Stockholm Hotel starting at 7:00 a.m. on May 22.

BioEquity Europe showcases a full slate of 60 mature and more than 30 newly formed innovator biopharma companies, as well as topical plenaries on the future of science and biomedical innovation in Europe featuring an international faculty of leaders from bioindustry, finance and the public sector. The 60 Presenting Companies have been hand-picked by BioCentury on the basis of investor validation, upcoming milestones and unpartnered assets. The slate of "Next Wave" companies features fresh opportunities for venture capital investment in the biotech space.

More than half a dozen plenaries and Q&A sessions are scheduled, including the 6th Annual BioCentury - Ernst & Young Face-Off. At this session, BioCentury will unveil its 11th annual "European Iceberg" report, which projects the forward demand for funding by Europe's clinical stage biotechnology companies, and Ernst & Young will provide analysis from its 27th annual "Beyond Borders Global Biotechnology Report." The Face-Off will be chaired by Susan Schaeffer, Editor of BioCentury, the Bernstein Report on BioBusiness, and Glen Giovannetti, Global Life Sciences Sector Leader at Ernst & Young. Other plenaries will focus on how European biotechs can better compete in early innovation and adapt to the changing healthcare ecosystem.

"The full slate of presenting companies, distinguished faculty and strong pre-registration numbers show a renewed interest in European biotechs by the investment community," said BioCentury Publisher Eric Pierce. "The compelling stories from the Class of 2013 coupled with high-impact discussions make BioEquity Europe 2013 a must-attend event for investors and business development and licensing professionals."

See the complete program, including the Presenting Company and plenary schedules, and a list of the 2013 faculty at http://www.biocentury.com/conferences/bioequityeurope/dates/schedule

The 2013 BioEquity Europe Presenting Companies
The Presenting Companies were screened using BioCentury's industry analysis and proprietary databases, including BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising ability, the prospect for key partnerships and proximity to potentially transformational milestones.

View the complete list of Full and Next Wave Presenting Companies at http://www.biocentury.com/conferences/bioequityeurope/companies/presentingcompanies.

The 2013 BioEquity Europe Sponsors & Regional Host Committee
This unique turf-neutral setting is made possible by the durable support of the region's life science organizations and BioEquity Europe's Sponsors. The Regional Host Committee is comprised of AstraZeneca plc, Awapatent, The Boston Consulting Group, County Administrative Board of Stockholm, Danske Bank, HealthCap, Industrifonden, Novo A/S, Stockholm Business Region and Swedish Orphan Biovitrum AB (SOBI).

The prestigious group of 2013 sponsors is anchored by Gold Sponsors Ernst & Young and Sofinnova Partners and Silver Sponsors AbbVie, ABG Sundal Collier, Abingworth, CMS, Edwards Wildman, Entrepreneurs Fund, Index Ventures, Merck Serono Ventures, NB Capital, Piper Jaffray, Roche Venture Fund and Sunstone Capital.

About BioCentury
Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, television, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioEquity Europe is one of three annual investor conferences organized by BioCentury. The next conference, NewsMakers in the Biotech Industry, will take place on Sept. 27, 2013, followed by Future Leaders in the Biotech Industry, on March 28, 2014. Both events will take place at the Millennium Broadway Hotel & Conference Center in New York City.

For more information, visit www.biocentury.com and www.biocenturytv.com.

About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. EBD Group's conferences include BIO-Europe, BIO-Europe Spring®, BioPharm, BioEquity Europe. EBD Group's Web-based, partnering service partneringONE™ is used at numerous third-party events around the world. EBD Group's consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in the U.S. and Europe.

About the Biotechnology Industry Organization
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.